These long-term findings in a large patient cohort show the sustained clinical efficacy and safety of autologous CD34+ hematopoietic stem-cell lentiviral gene therapy for ADA-SCID, indicating that it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback